Table of Contents
- Trial overview
- Who is being studied
- What the study is measuring
- Study treatment and comparison
- Study design and phase
- Why this trial matters
Trial overview
The available trial for Lufepirsen is NCT05966493, titled a clinical trial to evaluate the safety and the efficacy of NEXAGON in subjects with persistent corneal epithelial defects (NEXPEDE-1).[1]
This study is authorised, which means it has been approved to move forward, and it is listed as a Phase 2 interventional trial.[1]
Who is being studied
The trial is focused on people with persistent corneal epithelial defects, a condition where the surface of the cornea does not heal normally.[1]
In simple terms, the cornea is the clear front part of the eye, and the study is looking at whether treatment can help this surface close and stay healed.[1]
The source data do not provide more detailed inclusion or exclusion rules, so the main target group we can confirm is subjects with this eye condition.[1]
What the study is measuring
The main outcome is the proportion of subjects who achieve corneal re-epithelialization that is maintained for at least 28 days.[1]
Corneal re-epithelialization means the cornea has formed a new surface layer again, which is a sign of healing.[1]
Researchers assess this using corneal fluorescein staining images reviewed by a central reading center (CRC), which is a group that checks images in a standard way.[1]
The brief summary also says the study is evaluating both safety and efficacy, meaning whether the treatment can be used safely and whether it helps the condition improve.[1]
Study treatment and comparison
The trial compares NEXAGON with a vehicle, which is a sterile gel without the active ingredient Lufepirsen.[1]
The vehicle contains poloxamer 407, sodium phosphate dibasic heptahydrate, potassium dihydrogen phosphate, and sterile water for injection, but it does not contain the API, meaning the active pharmaceutical ingredient.[1]
NEXAGON is given topically, which means it is applied directly to the eye surface.[1]
The source lists two NEXAGON dosing entries, 0.02 mg/Kg topical and 0.18 mg topical, but it does not explain here how these are assigned across groups.[1]
Study design and phase
This is an interventional study, so researchers actively give a treatment and compare results between groups.[1]
It is a Phase 2 trial, which usually means the study is early enough to still focus on safety while also testing whether the treatment shows signs of benefit.[1]
The planned enrollment is 120 subjects, giving the study a moderate size for this stage of research.[1]
Why this trial matters
Persistent corneal epithelial defects can be difficult to heal, so a trial like this is important because it looks at whether the corneal surface can close and remain healed for a meaningful period.[1]
For patients, the key point is that the study is not just checking short-term improvement; it is measuring whether healing lasts for 28 days or more.[1]
At this time, the information provided describes one authorised Phase 2 study of Lufepirsen in this eye condition, so the clinical trial picture is focused and specific.[1]
